Pure ground-glass nodules are faint, cloud-like lesions that appear on CT scans without any solid, opaque core. They have become increasingly common discoveries as low-dose CT lung screening spreads worldwide, and they represent a spectrum of disease ranging from atypical adenomatous hyperplasia (AAH) and adenocarcinoma in situ (AIS)—considered non-invasive, indolent lesions—through minimally invasive adenocarcinoma (MIA) to fully invasive adenocarcinoma (IAC). The clinical dilemma is acute. Non-invasive lesions may never harm a patient and can often be safely watched with serial imaging, while invasive ones typically require surgical resection, ranging from wedge resection to lobectomy. Yet on conventional CT images, these lesions can look nearly identical. Resecting every nodule would burden patients with complications, costs and anxiety; watching every nodule could delay treatment for those that are quietly becoming invasive.

The Tianjin team, led by Jun Lv and corresponding author Hong Zhang, attacked the problem on two fronts: better images and smarter analysis of those images. On the imaging side, the researchers used a technique called large matrix target reconstruction. Standard chest CT images are reconstructed at a 512 × 512 pixel matrix over a field of view of roughly 350 millimetres, yielding a pixel size of about 0.68 millimetres. For nodules smaller than 15 millimetres, this coarse resolution produces partial volume effects—where each pixel averages tissue signals together—that blur the subtle internal architecture radiologists rely on. Instead, the team reconstructed targeted images at a 1,024 × 1,024 matrix over a reduced 70-millimetre field of view centred on the nodule, cutting pixel size to approximately 0.068 millimetres. That is roughly a tenfold improvement in spatial resolution, allowing finer delineation of tumour margins, minute solid components and microvascular changes that conventional reconstructions can miss.

On the analytical side, the researchers embraced radiomics, the practice of extracting hundreds of quantitative features from medical images—features invisible to the human eye but potentially reflective of underlying tumour biology. From each lesion, the team’s pipeline, built on the open-source PyRadiomics library, extracted a remarkable 1,834 quantitative features. These fell into three broad categories: shape descriptors capturing the three-dimensional geometry of the nodule; first-order statistics describing the distribution of CT intensity values within it; and texture features quantifying spatial heterogeneity, computed from matrices such as the grey-level co-occurrence matrix, grey-level run length matrix, grey-level size zone matrix, grey-level dependence matrix and neighbouring grey-tone difference matrix. Because so many features invite statistical overfitting, the team applied least absolute shrinkage and selection operator (LASSO) regression with ten-fold cross-validation, which whittled the feature set down to 11 non-zero features carrying the most predictive information.

The study population consisted of 297 patients—86 men and 211 women, aged 19 to 76 with a mean age of 56—all of whom underwent surgical resection at Tianjin Chest Hospital between March 2021 and June 2024, providing the pathological “ground truth” against which the models were tested. After exclusions for benign lesions, prior malignancies, solid or part-solid nodules, lesions larger than 1.5 centimetres and poor image quality, the final cohort comprised 93 patients with non-invasive lesions (AAH or AIS) and 204 with invasive ones (MIA or IAC). The cohort was split 7:3 into a training set of 207 cases and a validation set of 90, using stratified random sampling to preserve the balance of pathological classes. Every pathological diagnosis was rendered by two board-certified thoracic pathologists with more than a decade of experience, blinded to imaging, working to the 2021 World Health Organization classification.

The clinical and imaging data alone told a compelling story. Invasive lesions were larger, averaging 17.2 millimetres in maximum diameter versus 14.5 millimetres for non-invasive ones, denser on CT—mean densities of −642 versus −671.5 Hounsfield units—and carried a much higher solid component ratio, 56.2 percent versus 35.3 percent. Invasive nodules were also more likely to be irregular in shape, lobulated, spiculated, associated with pleural indentation, microvascular changes and cavitation, and their owners were more likely to be older, male and to have a smoking history. Multivariate logistic regression distilled these down to three independent predictors: maximum lesion diameter, median CT value and the solid component ratio. Each millimetre of added diameter raised the odds of invasiveness by roughly 77.6 percent, and each Hounsfield unit of increased median density raised them by 1.5 percent.

The models themselves, however, delivered the headline result. Built in Python with logistic regression and five-fold cross-validation, the radiomics-only model achieved an area under the receiver operating characteristic curve (AUC) of 0.861 (95 percent confidence interval 0.811–0.912) in the training set and 0.790 (95 percent CI 0.687–0.892) in the validation set, with sensitivity of 78.7 percent and specificity of 65.5 percent in validation. The combined model, integrating clinical features with radiomics, reached an AUC of 0.861 (95 percent CI 0.809–0.913) in training and 0.810 (95 percent CI 0.709–0.912) in validation, with validation sensitivity climbing to 90.2 percent. In the validation cohort, the combined model significantly outperformed both the radiomics-only and clinical-only models, while decision curve analysis showed the combined model delivered the greatest net clinical benefit whenever the decision threshold probability exceeded 40 percent—the very zone where surgeons wrestle with the operate-versus-observe choice. Calibration curves and the Hosmer–Lemeshow test confirmed the model’s predictions tracked actual outcomes well in both cohorts.

To make the tool usable at the bedside, the team packaged their findings into a nomogram—a graphical calculator that assigns points for a patient’s clinical profile and radiomics signature, sums them, and converts the total into a probability of invasiveness. The authors argue its greatest value lies in reclassifying intermediate-risk nodules, the ambiguous middle ground where management decisions are hardest. By sharpening the risk estimate in these cases, the tool could reduce both unnecessary operations on indolent lesions and delayed interventions on minimally invasive cancers, where early surgery offers the best chance of cure.

The researchers were candid about the technical subtleties in their data. Correlation analysis showed that some first-order radiomics features, such as the median and mean intensity statistics, correlated strongly with the conventional CT density measurements (correlation coefficients of 0.81 to 0.89), raising the question of redundancy. Yet higher-order texture features—such as dependence entropy and grey-level non-uniformity—showed weak correlations with clinical HU variables and captured spatial patterns of tumour heterogeneity that simple density averages cannot. Variance inflation factor analysis confirmed acceptable multicollinearity in the combined model, and the modest but consistent improvement in validation performance suggested the radiomics features contributed genuinely complementary information, reflecting tumour microarchitecture rather than mere intensity.

The study’s limitations are real and the authors acknowledge them squarely. It was retrospective and single-centre, relying on a single CT scanner—the Philips Brilliance iCT 256—and a specific reconstruction protocol, which may limit generalisability. Validation was internal rather than external, and the three-dimensional tumour segmentations were performed manually by experienced radiologists, a laborious process that can introduce variability, though inter-observer Dice similarity coefficients of 0.85 to 0.92 indicated excellent agreement. The team also lacked a direct comparison arm using conventional 512-matrix reconstruction, so the precise incremental benefit of the high-resolution technique remains to be quantified in a controlled design. The authors call for prospective, multicentre validation across diverse scanners and populations, noting also that subsolid nodule behaviour differs between Asian and Western populations, with higher pGGN prevalence and overdiagnosis concerns in East Asia.

Even with those caveats, the work represents a meaningful step toward precision management of a lesion type that millions of screening participants now carry. The convergence of ultra-high-resolution targeted reconstruction—essentially giving the radiologist a magnifying glass with a thousand-fold finer grid—and statistical learning over thousands of quantitative image features offers a non-invasive window into tumour biology that previously required a scalpel to obtain. If external validation confirms these results, the humble chest CT, paired with algorithms running quietly in the background, could become the difference between watchful waiting and the operating room for patients with tiny ground-glass nodules—and could do so before a single cell has breached a basement membrane.

Recent advances in the field of radiomics—the comprehensive extraction of quantitative features from medical images—offer promising avenues to overcome these challenges. By harnessing high-throughput data derived from computed tomography (CT) scans, radiomics can reveal subtle imaging biomarkers that are often imperceptible to the human eye. These biomarkers, when combined with clinical indicators, may enable more precise and personalized predictions regarding LVI status in patients with invasive LUAD.

A pioneering study published in BMC Cancer has explored the integration of intratumoral and peritumoral CT radiomics features to develop predictive models for LVI in LUAD patients. The investigators analyzed CT images from a cohort of over 600 patients across two institutions, extracting an extensive array of more than 1,200 quantitative radiomic features from distinct tumor regions. This comprehensive approach allowed for a detailed morphological and textural characterization of both the tumor bulk and its surrounding microenvironment, which is critically implicated in tumor invasion dynamics.

The research team divided their patient population into training, internal, and external validation cohorts, enabling robust assessment of the model’s generalizability across diverse clinical settings. Utilizing advanced machine learning techniques, they constructed three distinct radiomics models: one focusing on the gross tumor alone, a second encompassing both gross tumor and peritumoral regions, and a third analyzing the peritumoral area in isolation. These models were evaluated based on their ability to discriminate LVI presence, measured through the area under the receiver operating characteristic curve (AUC).

Among the three approaches, the model incorporating both intratumoral and peritumoral features demonstrated superior predictive performance. This combined gross tumor and peritumoral (GPT) model revealed AUC values of 0.83 in the training set and maintained robust prediction capabilities with AUCs of 0.79 and 0.75 in internal and external validation sets, respectively. These findings underscore the clinical value of assessing not only the tumor itself but also its interface with the surrounding tissue, a region known to harbor critical biological interactions facilitating vascular and lymphatic spread.

In parallel, the study also identified key clinical parameters independently associated with LVI through rigorous statistical analysis. The preoperative carcinoembryonic antigen (CEA) level, tumor diameter, and the presence of spiculation on CT scans emerged as significant predictors. Incorporating these clinical indicators alongside the radiomic signature resulted in a composite predictive model with further enhanced accuracy. The integrated model yielded AUCs of 0.84, 0.82, and 0.77 across the training, internal, and external cohorts, respectively, outperforming models based solely on imaging or clinical data.

This multifaceted approach highlighting the synergy between image-derived radiomic features and conventional clinical factors represents a substantial step forward in the non-invasive preoperative assessment of LUAD. From a clinical perspective, the ability to predict LVI status before surgical intervention could enable thoracic oncologists to stratify patients according to risk, personalize therapeutic regimens, and potentially improve survival outcomes by identifying those who may benefit from more aggressive treatments or closer postoperative surveillance.

The methodology employed in this study involved comprehensive feature extraction from high-resolution CT images, capturing a spectrum of matrix-based texture descriptors and wavelet transformations, which provide deep insights into tumor heterogeneity. Radiomic features related to shape, intensity, and texture likely reflect the complex biological processes underpinning tumor growth and vascular invasion, offering a quantitative surrogate marker unattainable through standard radiological interpretation.

Furthermore, the inclusion of peritumoral radiomics is especially notable, as the tumor microenvironment plays a pivotal role in facilitating cancer progression and metastasis. By extending analysis beyond the tumor boundaries, the researchers tapped into spatial patterns of tissue alterations adjacent to the tumor that may signal early invasion of lymphovascular structures. These pioneering insights highlight the necessity of looking beyond conventional tumor metrics to fully characterize malignant potential.

The clinical applicability of such predictive models holds profound implications for advancing precision medicine in lung cancer care. As lung adenocarcinoma comprises a heterogeneous group of tumors with variable behavior, preoperative LVI prediction via non-invasive imaging biomarkers could inform decisions surrounding surgical resection margins, lymph node dissection extent, and the necessity for neoadjuvant therapies. This stratification may ultimately reduce overtreatment and associated morbidities while ensuring optimal oncologic control for high-risk patients.

Moreover, the study sets a precedent for the integration of big data analytics, artificial intelligence, and clinical oncology, showcasing a translational framework whereby computational tools augment physician capabilities. Radiomics, when validated in large multicenter cohorts as exemplified in this investigation, can become an indispensable component of the oncologic diagnostic arsenal, fostering more nuanced risk assessments and guiding tailored interventions.

Despite the encouraging results, certain challenges remain for the widespread clinical implementation of radiomics models. Standardization of imaging protocols, reproducibility of feature extraction algorithms, and prospective validation in randomized clinical trials are necessary to cement the role of radiomics as a standard diagnostic tool. Additionally, interdisciplinary collaboration among radiologists, oncologists, bioinformaticians, and machine learning experts will be critical to overcome technical and methodological hurdles.

Looking ahead, the integration of radiomics with emerging molecular and genomic biomarkers could further enhance prediction accuracy and provide a holistic view of tumor biology. Combining imaging phenotypes with genetic profiles may unravel novel mechanisms underlying lymphovascular invasion and identify new therapeutic targets. This multimodal approach embodies the future of oncology, leveraging the convergence of data science and molecular medicine.

In conclusion, this innovative study provides compelling evidence that CT radiomics models incorporating intratumoral and peritumoral features, combined with key clinical parameters, offer a powerful non-invasive method for predicting lymphovascular invasion in invasive lung adenocarcinoma. By facilitating early identification of patients at higher risk for poor prognosis, this approach promises to refine risk stratification, tailor treatment strategies, and ultimately improve clinical outcomes. The findings underscore the transformative potential of radiomics in lung cancer management and highlight the importance of ongoing research bridging advanced imaging analytics with pragmatic clinical applications.

Subject of Research: Non-invasive prediction of lymphovascular invasion in invasive lung adenocarcinoma using intratumoral and peritumoral CT radiomics combined with clinical indicators

Article Title: The clinical value of predicting lymphovascular invasion in patients with invasive lung adenocarcinoma based on the intratumoral and peritumoral CT radiomics models

Article References:
Lin, M., Zhao, C., Huang, H. et al. The clinical value of predicting lymphovascular invasion in patients with invasive lung adenocarcinoma based on the intratumoral and peritumoral CT radiomics models. BMC Cancer 25, 1752 (2025). https://doi.org/10.1186/s12885-025-15128-2

Image Credits: Scienmag.com

DOI: 10.1186/s12885-025-15128-2 (Published 12 November 2025)